LSKB Still Upbeat On Rivoceranib Despite ANGEL Failure In Late-Line Gastric Cancer

 
• By Jung Won Shin
  
Closed up finger on keyboard with word CLINICAL TRIALS
Rivoceranib Faces Delay After Primary Endpoint Failure • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D